Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | TAF1 | P21675 | 1/20 | 0.42 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.42 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | KDM6B | O15054 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19639677 | 0.81 | LMNA (0.42) | SMN1; SMN2HRH3SCN9A | |
| SCHEMBL17753933 | 0.80 | SMN1; SMN2 (0.61) | SMN1; SMN2HTTABCB1ABCC1ABCG2 | |
| Hydrochloric Acid SCHEMBL19639681 | 0.79 | SMN1; SMN2 (0.60) | SMN1; SMN2HTTABCB1ABCC1ABCG2 | |
| SCHEMBL19658782 | 0.76 | TAF1 (0.54) | SMN1; SMN2HTTABCB1ABCC1ABCG2 | |
| SCHEMBL19639675 | 0.76 | TAF1 (0.54) | SMN1; SMN2HTTABCB1ABCC1ABCG2 | |
| SCHEMBL17749034 | 0.75 | SMN1; SMN2 (0.52) | SMN1; SMN2HTTABCB1ABCC1ABCG2 | |
| SCHEMBL3485939 | 0.74 | GPR119 (0.64) | SMN1; SMN2HTT | |
| SCHEMBL19652231 | 0.74 | TAF1 (0.54) | SMN1; SMN2HTTABCB1ABCC1ABCG2 | |
| SCHEMBL19652270 | 0.74 | TAF1 (0.50) | SMN1; SMN2HTTABCB1ABCC1ABCG2 | |
| SCHEMBL9520849 | 0.72 | SMN1; SMN2 (0.73) | SMN1; SMN2HTTABCB1ABCC1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| EP-3218376-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | Genentech, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| WO-2016077375-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | SMN1; SMN2 1221/4885HTT 832/4885ABCB1 1222/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | SMN1; SMN2 1221/4885HTT 832/4885ABCB1 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.